128 related articles for article (PubMed ID: 16214453)
1. Comparison of efficacy and safety assessment of fluvastatin in patients <65 years versus > or =65 years of age.
Bruckert E; Verpilleux MP; Dejager S; Isaacsohn J
Am J Cardiol; 2005 Oct; 96(8):1142-8. PubMed ID: 16214453
[TBL] [Abstract][Full Text] [Related]
2. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials.
Winkler K; Ablethauser CB; Gimpelewicz C; Bortolini M; Isaacsohn JL
Clin Ther; 2007 Sep; 29(9):1987-2000. PubMed ID: 18035198
[TBL] [Abstract][Full Text] [Related]
3. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials.
Holdaas H; Wanner C; Abletshauser C; Gimpelewicz C; Isaacsohn J
Int J Cardiol; 2007 Apr; 117(1):64-74. PubMed ID: 16889855
[TBL] [Abstract][Full Text] [Related]
4. Long-term event monitoring study of fluvastatin in Japanese patients with hypercholesterolemia: Efficacy and incidence of cardiac and other events in elderly patients (≥ 65 years old).
Itakura H; Nakaya N; Kusunoki T; Shimizu N; Hirai S; Mochizuki S; Ishikawa T
J Cardiol; 2011 Jan; 57(1):77-88. PubMed ID: 21067897
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
[TBL] [Abstract][Full Text] [Related]
6. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study.
Norby GE; Holme I; Fellström B; Jardine A; Cole E; Abedini S; Holdaas H;
Arthritis Rheum; 2009 Apr; 60(4):1060-4. PubMed ID: 19333947
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of fluvastatin.
Peters TK
Br J Clin Pract Suppl; 1994 Dec; (77):20-3. PubMed ID: 19489170
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of fluvastatin.
Peters TK
Br J Clin Pract Suppl; 1996 Jan; 77A():20-3. PubMed ID: 8729586
[TBL] [Abstract][Full Text] [Related]
9. Fluvastatin reduces the impact of diabetes on long-term outcome after coronary intervention--a Lescol Intervention Prevention Study (LIPS) substudy.
Arampatzis CA; Goedhart D; Serruys PW; Saia F; Lemos PA; de Feyter P;
Am Heart J; 2005 Feb; 149(2):329-35. PubMed ID: 15846273
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
11. The renal safety profile of fluvastatin: results of a pooled analysis.
Holdaas H; Wanner C; Abletshauser C; Gimpelewicz C; Isaacsohn J
Ren Fail; 2006; 28(6):487-92. PubMed ID: 16928618
[TBL] [Abstract][Full Text] [Related]
12. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
13. Fluvastatin blunts the effect of a high-fat meal on plasma triglyceride and high-sensitivity C-reactive protein concentrations in patients at high risk for cardiovascular events.
Liu L; Zhao SP; Hu M; Li JX
Coron Artery Dis; 2007 Sep; 18(6):489-93. PubMed ID: 17700222
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
15. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation.
Holdaas H; Fellström B; Jardine AG; Nyberg G; Grönhagen-Riska C; Madsen S; Neumayer HH; Cole E; Maes B; Ambühl P; Logan JO; Staffler B; Gimpelewicz C;
Nephrol Dial Transplant; 2005 May; 20(5):974-80. PubMed ID: 15784644
[TBL] [Abstract][Full Text] [Related]
17. Fluvastatin treatment is not associated with an increased incidence of cancer.
Stein EA; Corsini A; Gimpelewicz CR; Bortolini M; Gil M
Int J Clin Pract; 2006 Sep; 60(9):1028-34. PubMed ID: 16939542
[TBL] [Abstract][Full Text] [Related]
18. Treatment of dyslipidaemias with fluvastatin.
Peters TK
Br J Clin Pract Suppl; 1994 Dec; (77):16-9. PubMed ID: 19514133
[TBL] [Abstract][Full Text] [Related]
19. Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality.
Soveri I; Holdaas H; Jardine A; Gimpelewicz C; Staffler B; Fellström B
Nephrol Dial Transplant; 2006 Aug; 21(8):2282-9. PubMed ID: 16574686
[TBL] [Abstract][Full Text] [Related]
20. Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
